[EN] ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS<br/>[FR] DÉRIVÉS D'ISOQUINOLÉINE EN TANT QU'INHIBITEURS DE SIK2
申请人:CANCER RESEARCH TECH LTD
公开号:WO2021084264A1
公开(公告)日:2021-05-06
Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, X1, X2, X3 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.
提供了化合物的公式I,以及其盐和溶剂合物:(I)其中R1、R2、R3、X1、X2、X3和Z在规范中有定义。这些化合物是盐诱导激酶(SIK),特别是SIK2的抑制剂,并且在治疗中非常有用,特别是在治疗增生性疾病、良性肿瘤、病理性血管生成、炎症性疾病或情况、肌肉骨骼疾病或情况、自身免疫疾病、血液疾病或情况、神经疾病或情况、精神障碍或代谢性疾病的治疗中。